QTTB241115P45000
- 3.57
- 0.000.00%
Q32 Bio Newsroom
Oppenheimer Maintains Q32 Bio(QTTB.US) With Buy Rating, Raises Target Price to $80
Q32 Bio Analyst Ratings
Wells Fargo Initiates Q32 Bio at Overweight With $95 Price Target
Wells Fargo Initiates Q32 Bio(QTTB.US) With Buy Rating, Announces Target Price $95
Piper Sandler Maintains Q32 Bio(QTTB.US) With Buy Rating, Maintains Target Price $60
Piper Sandler Sticks to Their Buy Rating for Q32 Bio (QTTB)
Piper Sandler Maintains Q32 Bio(QTTB.US) With Buy Rating, Raises Target Price to $60
Analysts Have Conflicting Sentiments on These Healthcare Companies: Edwards Lifesciences (EW), Immunovant (IMVT) and Q32 Bio (QTTB)
Analysts Are Bullish on These Healthcare Stocks: Q32 Bio (QTTB), Wave Life Sciences (WVE)
Buy Rating on Q32 Bio: Promising Clinical Trials and Market Potential for Bempikibart
Piper Sandler Maintains Q32 Bio(QTTB.US) With Buy Rating, Maintains Target Price $45
Q32 Bio (QTTB) Receives a Buy From Piper Sandler
Q32 Bio (QTTB) Receives a Rating Update From a Top Analyst
Guggenheim Initiates Coverage On Q32 Bio With Buy Rating, Announces Price Target of $100
Q32 Bio Analyst Ratings
Q32 Bio (QTTB.US) was first covered by Leerink Partners, which gave it an superior market rating, with a target price of $54.00.
Q32 Bio Analyst Ratings
Leerink Partners Initiates Coverage On Q32 Bio With Outperform Rating, Announces Price Target of $54
Buy Rating Justified by Q32 Bio's Promising Pipeline and Market Potential
Q32 Bio (QTTB) Gets a Buy From Oppenheimer